- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04291014
Light Therapy for PD - Dose Selection
December 13, 2022 updated by: Aleksandar Videnovic, MD, Massachusetts General Hospital
A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's Disease
This study aims to determine the most effective dose of light therapy to improve sleep in people with Parkinson's Disease.
Four groups of participants will receive bright-white or dim-red light therapy at different times throughout the day.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a 16-week, randomized, phase II, parallel-group, dose-selection clinical trial of LT in participants with PD and co-existing sleep disruption using a comparative selection trial design.
Study Type
Interventional
Enrollment (Anticipated)
144
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Barrow Neurological Institute
-
-
California
-
Irvine, California, United States, 92697
- UC Irvine
-
Sacramento, California, United States, 95817
- UC Davis
-
-
Connecticut
-
Fairfield, Connecticut, United States, 06824
- Yale University
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in St. Louis
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell
-
New York, New York, United States, 10029
- Mount Sinai - Icahn School of Medicine
-
Rochester, New York, United States, 14642
- University of Rochester
-
Stony Brook, New York, United States, 11794
- SUNY Stonybrook
-
Syracuse, New York, United States, 13210
- SUNY Upstate
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27104
- Wake Forest University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati
-
Columbus, Ohio, United States, 43221
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
43 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of idiopathic PD as defined by the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease;
- PD Hoehn and Yahr stage 2-4;
- A score of 2 (mild) or above on the Sleep Problems question of the MDS-UPDRS Part 1;
- Stable dose of all PD medications for at least 30 days prior to randomization;
- Willingness to wear an Actiwatch and complete daily sleep logs;
- Age 45 or above
Exclusion Criteria:
- Atypical or secondary forms of parkinsonism;
- Co-existent significant sleep apnea at screening, as determined by the PI's clinical assessment; adequately treated sleep apnea, as assessed by sleep apnea machine download (CPAP download) will be permitted;
- Co-existent symptomatic restless legs syndrome (RLS) (as assessed by the International Classification of Sleep Disorders (ICDS) diagnostic criteria for RLS) at screening;
- Cognitive impairment as determined by a Mini Mental State Examination score <25 at screening;
- Presence of moderate depression defined as a Beck Depression Inventory II (BDI-II) score ≥20 at screening;
- Current untreated hallucinations or psychosis (drug-induced or spontaneous) with a score of 2 or above on the Hallucinations and Psychosis question of the MDS-UPDRS Part 2;
- Use of hypno-sedative drugs for sleep or stimulants, unless the participant has been on a stable dose for at least 60 days prior to the screening;
- Ongoing or recent (within 30 days prior to screening) Cognitive Behavioral Therapy for Insomnia;
- Use of antidepressants, unless the participant has been on a stable dose for at least 60 days prior to the screening;
- Work hours between 10 PM and 6 AM, within 60 days prior to randomization or anticipated during the 16 weeks after screening;
- Travel between 3 or more time zones within 45 days prior to study screening or anticipated such travel during the 16 weeks after screening;
- Unstable or serious medical illness;
- History of significant eye trauma or disease, retinopathy, or cataract Grade 4 that would significantly affect transmission or processing of light through either eye;
- Current use, use at any time during study participation, or use within the 30 days prior to screening of photosensitizing or other medications that in the opinion of the investigator would interfere with the safety of the participant during the trial, including: amiodarone, porfimer, psoralens, chlorpromazine, quinidine, demeclocycline, temoporfin, tetracycline, fleroxacin, oral isoretinoin, voriconazole, nalidixic acid, thioridazine, St. John's wort, ofloxacin, and piroxicam;
- Pregnant women will be excluded from participation; if a participant is pre-menopausal, a urine pregnancy test will be conducted at randomization to determine eligibility.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BWLT once daily
Participants in this arm will receive bright white light therapy daily once a day (in the evening)
|
SunRay light boxes will be used to administer the light therapy.
|
Experimental: BWLT twice daily
Participants in this arm will receive bright white light therapy daily twice a day (morning and evening).
|
SunRay light boxes will be used to administer the light therapy.
|
Experimental: BWLT weekly
Participants in this arm will receive bright white light therapy once weekly (in the evening).
|
SunRay light boxes will be used to administer the light therapy.
|
Experimental: DRLT twice daily
Participants in this arm will receive dim red light twice daily (morning and evening).
|
SunRay light boxes will be used to administer the light therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PDSS-2
Time Frame: 8 weeks
|
The PDSS-2 is a 15-question instrument designed to simultaneously capture the multidimensional aspects of sleep-related problems and changes in sleep quality.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS-16
Time Frame: 8 weeks
|
The PFS-16 is a patient-rated scale that measures fatigue.
The scale allows the measurements of the presence of fatigue (seven items) and its impact on daily function (nine items).
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat Disord. 2005 Jan;11(1):49-55. doi: 10.1016/j.parkreldis.2004.07.007.
- Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, Hulsmann J, Martinez-Martin P, Chaudhuri KR. Parkinson's disease sleep scale--validation of the revised version PDSS-2. Mov Disord. 2011 Mar;26(4):644-52. doi: 10.1002/mds.23476. Epub 2011 Feb 10.
- Willis GL, Turner EJ. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol Int. 2007;24(3):521-37. doi: 10.1080/07420520701420717.
- Paus S, Schmitz-Hubsch T, Wullner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's disease: a pilot study. Mov Disord. 2007 Jul 30;22(10):1495-1498. doi: 10.1002/mds.21542.
- Terman M, Terman JS. Bright light therapy: side effects and benefits across the symptom spectrum. J Clin Psychiatry. 1999 Nov;60(11):799-808; quiz 809.
- Gallin PF, Terman M, Reme CE, Rafferty B, Terman JS, Burde RM. Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy. Am J Ophthalmol. 1995 Feb;119(2):202-10. doi: 10.1016/s0002-9394(14)73874-7.
- Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017 Apr 1;74(4):411-418. doi: 10.1001/jamaneurol.2016.5192.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 11, 2020
Primary Completion (Actual)
November 12, 2022
Study Completion (Anticipated)
April 1, 2023
Study Registration Dates
First Submitted
February 27, 2020
First Submitted That Met QC Criteria
February 27, 2020
First Posted (Actual)
March 2, 2020
Study Record Updates
Last Update Posted (Estimate)
December 14, 2022
Last Update Submitted That Met QC Criteria
December 13, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN110 1U01NS114001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
This trial will follow the NINDS policy for data sharing.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatigue
-
Bakulev Scientific Center of Cardiovascular SurgeryFoundation for the Support of Physical Culture and Sports BECOME A CHAMPION; Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPIONNot yet recruitingEfficacy, Self | Fatigue, Mental | Fatigue; Muscle, Heart | Fatigue; CombatRussian Federation
-
Universita di VeronaUniversity of Southern CaliforniaCompletedDiet, Healthy | Fasting | Fatigue, Mental | Fatigue; Muscle, HeartItaly
-
University of ZurichRecruitingVocal FatigueSwitzerland
-
KU LeuvenCompleted
-
Société des Produits Nestlé (SPN)Maastricht University Medical CenterCompleted
-
University of Applied Sciences for Health Professions...University of Wisconsin, MilwaukeeCompleted
-
Taoyuan General HospitalCompleted
-
Alaa Yousri Mahmoud AtiaUnknownMuscle FatigueEgypt
-
University Hospital, Clermont-FerrandLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques...CompletedNeuromuscular FatigueFrance
-
Central Hospital, Nancy, FranceUniversity of Lorraine; Institut National de Recherche et de Sécurité, Nancy...Unknown
Clinical Trials on SunRay Light Boxes
-
University of California, San DiegoCompletedDiabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillPatient-Centered Outcomes Research Institute; University of Alabama at Birmingham and other collaboratorsCompletedRheumatoid ArthritisUnited States
-
Milton S. Hershey Medical CenterCompleted
-
Medical College of WisconsinActive, not recruitingType 2 DiabetesUnited States
-
University of Texas Southwestern Medical CenterAmerican Heart AssociationRecruitingHeart FailureUnited States
-
State University of New York at BuffaloCompleted
-
University of ArkansasActive, not recruitingDiabetes Mellitus, Type 2 | Food InsecurityUnited States
-
Icahn School of Medicine at Mount SinaiRecruitingMild Cognitive ImpairmentUnited States
-
China Medical University HospitalNot yet recruiting
-
University Hospital, Strasbourg, FranceRecruiting